182 related articles for article (PubMed ID: 29649930)
1. Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
Almeida KJ; Barreto-Soares RV; Campos-Sousa RN; Campos-Sousa MG; Bor-Seng-Shu E
Mult Scler; 2018 Jun; 24(7):1002-1004. PubMed ID: 29649930
[TBL] [Abstract][Full Text] [Related]
2. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
[No Abstract] [Full Text] [Related]
3. Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma.
Kaye AE; Hawkes ED; Gout II; El-Amir AN; Neffendorf JE
Mult Scler Relat Disord; 2018 Nov; 26():74-76. PubMed ID: 30237107
[TBL] [Abstract][Full Text] [Related]
4. Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
Foley RW; Tagg NT; Schindler MK; Fenton KM; Reich DS; Cortese I; Mowry EM
Mult Scler; 2017 Sep; 23(10):1424-1427. PubMed ID: 28639536
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
Lanza Cariccio V; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
[TBL] [Abstract][Full Text] [Related]
6. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
[TBL] [Abstract][Full Text] [Related]
8. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
[TBL] [Abstract][Full Text] [Related]
9. Infusion-related reactions during Natalizumab treatment: Do we still need a post-infusion observation period?
Sacco R; Disanto G; Maraffi I; Candrian U; Kamm CP; Rossi S; Schwegler G; Gallo A; Gobbi C; Zecca C
Mult Scler Relat Disord; 2020 Feb; 38():101523. PubMed ID: 31743848
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
11. Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study.
D'Amico E; Zanghì A; Calogero AE; Patti F
Mult Scler; 2021 Dec; 27(14):2284-2287. PubMed ID: 33870777
[TBL] [Abstract][Full Text] [Related]
12. Cerebral abscess in a multiple sclerosis patient during treatment with natalizumab.
Durmus B; Van Goethem J; Vercruyssen A; De la Meilleure G; Jadoul C; Willekens B
Acta Neurol Belg; 2020 Feb; 120(1):215-217. PubMed ID: 30953297
[No Abstract] [Full Text] [Related]
13. Natalizumab treatment for multiple sclerosis inducing a toxic acute myocardial damage. Is there any relationship?
Fama' F; Dattola V; Cicciu' M; Buccafusca M; Russo M; Lo Presti D; Dattilo G; Di Bella G
Int J Cardiol; 2016 Mar; 206():127-8. PubMed ID: 26788687
[No Abstract] [Full Text] [Related]
14. Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
Yamout BI; Abou Zeid N; Taha AJ; Zeineddine MM; Khoury SJ
Mult Scler Relat Disord; 2016 Sep; 9():122-4. PubMed ID: 27645358
[TBL] [Abstract][Full Text] [Related]
15. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
Miranda Acuña JA; Weinstock-Guttman B
Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
[TBL] [Abstract][Full Text] [Related]
16. Emergence of rheumatoid arthritis following exposure to natalizumab.
Su E; Novic J; Han MH
Mult Scler Relat Disord; 2020 May; 40():101936. PubMed ID: 31982664
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
[TBL] [Abstract][Full Text] [Related]
18. Reversible hyporegenerative anemia during natalizumab treatment.
Monteleone F; Buccisano F; Boffa L; Buttari F; Di Veroli A; Borriello G; Rossi S; Centonze D
Mult Scler; 2015 Feb; 21(2):257-8. PubMed ID: 25186208
[No Abstract] [Full Text] [Related]
19. Natalizumab in relapsing-remitting multiple sclerosis.
Outteryck O
Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
Diem L; Hoepner R; Bagnoud M; Salmen A; Chan A; Friedli C
J Neuroimmunol; 2021 Apr; 353():577505. PubMed ID: 33548621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
